Pages
Blogroll
- Blood Pressure Risk Factors
- Electric mobility scooters
- Hair Growth Product Reviews
- Hoveround Wheelchairs
- Medical Scales
- Mortgage modification trial payments
- NBA Basketball Betting
- Nursing career
- Pancreas Cancer
- Prevent Cancer
- Prostate Cancer Treatment Side Effects
- Type 2 Diabetes Mellitus
Categories
- Cancer Risk
- Cells and Organs
- General Information
- Prostate Help Organizations
- UK Prostate Cancer
- Uncategorized
Archives
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Meta
In a sharply worded letter to the Centers for Medicare & Medicaid Services, the American Society of Clinical Oncology takes the federal agency to task for conducting a coverage review of the Provenge prostate cancer vaccine. You may recall that CMS unexpectedly disclosed plans for a National Coverage Analysis in late June in response to inquiries from regional Medicare programs about the novel therapy.
Ever since, CMS has been bombarded with comments from patients, doctors and investors, among others. The vast majority express concern that CMS will somehow limit coverage next year, although a review of the $93,000 annual price tag per patient is not supposed to factor into the review (back story). In his letter, ASCO ceo Allen Lichter complains the reasoning given for the review is wa…
Original post by Pharmalot and software by Elliott Back
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.